Dexcom (DXCM) Hits New 52-Week High and Low at $102.10

Dexcom (NASDAQ:DXCM)’s share price reached a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $102.10 and last traded at $100.13, with a volume of 55313 shares. The stock had previously closed at $99.42.

Several research firms recently issued reports on DXCM. Piper Jaffray Companies increased their target price on Dexcom to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday. JPMorgan Chase & Co. raised Dexcom from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $80.00 to $115.00 in a research note on Friday, June 8th. TheStreet raised Dexcom from a “d” rating to a “c-” rating in a research note on Thursday, May 10th. Bank of America began coverage on Dexcom in a research note on Friday, May 11th. They set a “buy” rating and a $100.00 target price on the stock. Finally, ValuEngine raised Dexcom from a “hold” rating to a “buy” rating in a research note on Thursday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Dexcom presently has a consensus rating of “Buy” and an average price target of $74.50.

The company has a debt-to-equity ratio of 0.79, a current ratio of 5.83 and a quick ratio of 5.42. The stock has a market cap of $8.37 billion, a PE ratio of -169.86 and a beta of -0.01.



Dexcom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.32). The company had revenue of $184.40 million for the quarter, compared to analyst estimates of $172.66 million. Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. Dexcom’s revenue for the quarter was up 29.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.49) EPS. research analysts predict that Dexcom will post -0.51 earnings per share for the current year.

In other news, Director Eric Topol sold 20,000 shares of the stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $100.10, for a total value of $2,002,000.00. Following the transaction, the director now owns 3,695 shares in the company, valued at approximately $369,869.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $73.04, for a total value of $730,400.00. Following the completion of the transaction, the insider now owns 521,674 shares in the company, valued at approximately $38,103,068.96. The disclosure for this sale can be found here. Insiders sold a total of 128,375 shares of company stock worth $11,114,875 in the last ninety days. 1.80% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC purchased a new position in shares of Dexcom in the 1st quarter valued at about $105,000. American International Group Inc. purchased a new position in shares of Dexcom in the 4th quarter valued at about $116,000. SG Americas Securities LLC purchased a new position in shares of Dexcom in the 1st quarter valued at about $175,000. CIBC Asset Management Inc purchased a new position in shares of Dexcom in the 1st quarter valued at about $220,000. Finally, Atria Investments LLC purchased a new position in shares of Dexcom in the 1st quarter valued at about $249,000.

Dexcom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply